Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Expands By 5.6%

Ascendis Pharma A/S (NASDAQ:ASND) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 3,770,000 shares, a growth of 5.6% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is currently 6.4 days.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $129.87 on Monday. The business’s 50 day moving average price is $129.15 and its 200-day moving average price is $132.72. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The firm has a market capitalization of $7.88 billion, a price-to-earnings ratio of -16.07 and a beta of 0.67.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $30,000. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $60,000. Signaturefd LLC boosted its stake in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the last quarter. Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter worth approximately $205,000. Finally, Rhumbline Advisers raised its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent research reports. Bank of America upped their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, JPMorgan Chase & Co. dropped their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.